GlaxoSmithKline (NYSE:GSK) Rating Reaffirmed
The brokerage firm has just set a target of $48 on GlaxoSmithKline (NYSE:GSK) shares. This is 19.20% from the previous close. In an analyst research report made public on 7 December, Argus kept steady their Buy rating on shares of GSK.
From a total of 3 analysts covering GlaxoSmithKline (NYSE:GSK) stock, 1 rate it a ”Buy”, 0 a “Sell”, and 3 a ”Hold”. This means that 25% of the ratings are positive. The highest target price is $49 while the lowest target price is $43. The mean of all analyst targets is $45.67 with a 6.75% above today’s ($40.28) stock price. GlaxoSmithKline was the topic of 6 analyst reports since September 8, 2015 according to the firm StockzIntelligence Inc. Credit Suisse upgraded shares on October 20 to “Neutral” rating. BNP Paribas upgraded GSK stock in a recent report from September 15 to “Neutral” rating.
The stock increased 0.74% or $0.29 during the last trading session, striking $40.28. Approximately 7,600 shares of stock traded hands. GlaxoSmithKline plc (ADR) (NYSE:GSK) has declined 13.10% since May 4, 2015 and is downtrending. It has underperformed by 12.02% the S&P500.
GlaxoSmithKline plc. is a healthcare firm that researches and develops pharmaceuticals, vaccines and consumer healthcare products. The company has a market cap of $97.23 billion. The Firm operates in two divisions: Pharmaceuticals and Vaccines, and Consumer Healthcare. It has 6.55 P/E ratio. The Pharmaceuticals segment develops and makes medicines to treat a range of acute and chronic diseases.
According to Zacks Investment Research, “GlaxoSmithKline is one of the world’s leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic.” Get a free copy of the Zacks research report on GlaxoSmithKline plc (ADR) (GSK).